Roche Advances Fenebrutinib With 16% CDP Reduction, Building A Broader MS Case Ahead Of FDA Review
The Catalyst Brief · Oct 22, 2026
Latest
Astellas Strikes More Than $400 Million AI Proteins Deal To Expand Early-Stage Discovery
The Catalyst Brief · Oct 21, 2026
GSK Wins FDA Approval For Hibsago In Chronic Hepatitis B, Opening A Six-Month Functional-Cure Option
The Catalyst Brief · Oct 21, 2026
SCRS Launches Eagle Insights Dashboard To Score Sponsor And CRO Site Relationships
The Catalyst Brief · Oct 21, 2026
Across the beats
- AI in Drug Discovery
AstraZeneca And Oracle Form AI Pact To Improve Clinical Trial Recruitment
The Catalyst Brief Oct 20, 2026 - Biopharmaceutical Industry
Pfizer Ends PF-06835375 Phase 2 In ITP, Leaving CXCR5 Program Direction Unclear
The Catalyst Brief Oct 20, 2026 - Biotech Innovation
Nature Study Programs Bacillus Subtilis With Plant-Made OMY, Enabling More Than 3,000-Fold Control Of Protein Synthesis
The Catalyst Brief Oct 21, 2026 - Healthcare Investment
Locust Walk Says China Reached 58% Of Licensing Deal Value In 2026, As U.S. Biotech M&A Hit $173 Billion Through Q3
The Catalyst Brief Oct 21, 2026 - Medical Technology
EY Says Medtech Reached About $650 Billion In 2025 Revenue, With Growth Concentrated In Commercial Leaders
The Catalyst Brief Oct 20, 2026 - Regulatory & Policy
Nigeria Confirms Imported Ebola Case, Expanding DRC-Linked Outbreak To Fifth Country
The Catalyst Brief Oct 21, 2026
Most read
Priority Health’s Collaboration with Color Health and Grail Aims to Transform Cancer Support for Employers
Jul 26, 2026
China Proposes Limits On Foreign Biopharma Platform Acquisitions, While Leaving Most Licensing Structures Untouched
Oct 16, 2026
Biopharmaceutical Industry
Paul Stoffels Returns To Galapagos Cell Therapy Program With Up To $240 Million Armed Deal
Oct 16, 2026
Vir Licenses Three T-Cell Engager Programs To Gilead In Deal Worth Up To $1.9 Billion
Oct 14, 2026
More coverage
Biotech InnovationNature Study Retools Human AGO2 Into ALTER, A C-to-U RNA Editor That Tops Cas13 Comparators In HEK293T Cells
The work, published in Nature Biotechnology, describes AGO-led targeted editing of RNA, or ALTER, which fuses human AGO2 to a C-to-U deaminase and uses guide RNAs designed to favor binding over cleavage. The study positions a human-protein scaffold as a possible way to reduce some translation risks associated with nonhuman RNA editors, including delivery and immunogenicity concerns.
The Catalyst BriefOct 21, 2026
Regulatory & PolicyFDA Signals GenAI Medical Devices May Face Physician-Like Competency Review, As Draft Policy Moves Ahead
Rick Abramson, director of FDA's Digital Health Center of Excellence, said at The MedTech Conference that generative AI tools create an "unbounded evaluation space" that does not fit the agency's established software-as-a-medical-device framework. He also said the FDA intends to draft policy after reviewing more than 300 comments on its August discussion paper, with draft guidance expected on the course of months.
The Catalyst BriefOct 21, 2026
Healthcare InvestmentLycia Targets $227.8 Million IPO To Fund Two Food Allergy Programs And A Graves' Disease Study
Lycia plans to sell 14.7 million shares at $16 to $18 apiece, with net proceeds projected at $227.8 million if the final price lands at the midpoint. The filing gives an unusually explicit use-of-proceeds plan, tying the raise to phase 2 work for LCA-0061, LCA-0062 and LCA-0321.
The Catalyst BriefOct 20, 2026
Regulatory & PolicyTrump Orders NIH Women’s Health Division, Adding White House Task Force Amid Funding Strain
The initiative promises to streamline research into understudied diseases in women, improve diagnostics and treatment, and expand accountability around sex as a biological variable in NIH-funded work. Its policy significance lies in pairing a visible White House directive with an unclear operating model at a time when funding for women’s health research has already come under pressure.
The Catalyst BriefOct 20, 2026
Biopharmaceutical IndustryGenmab Faces A Darzalex Revenue Cliff As Petosemtamab And Rina-S Readouts Approach
Genmab executives and investors are framing the company’s next phase around a narrow set of oncology assets ahead of U.S. Darzalex patent expiry in 2029. The near-term question is less whether the cliff exists than whether upcoming data can compress the revenue gap fast enough to keep Genmab growing beyond it.
The Catalyst BriefOct 20, 2026
Biotech InnovationAbbVie Posts 30.2% Endoscopic Remission For ABBV-466, Beating Skyrizi In Midphase Crohn’s Trial
In a 300-patient study, 30.2% of people on ABBV-466 achieved endoscopic remission at Week 12, compared with 21.3% on Skyrizi and 18.0% on trosunilimab alone. AbbVie is already running a larger 2,000-patient phase 2 program and has said interim looks could shape plans for phase 3 before the study ends.
The Catalyst BriefOct 20, 2026
AI in Drug DiscoveryLilly Signs Up To $1.1 Billion Metis Deal, Extending Its AI-Enabled Delivery Push
The collaboration centers on Metis’ AiLNP platform, which the company says combines a large lipid library, end-to-end screening and a lipid language model to design lipid nanoparticles. For Lilly, the deal fits a pattern: pairing AI investments with a series of delivery-focused partnerships and acquisitions as drug modalities become harder to deliver effectively.
The Catalyst BriefOct 20, 2026
Biopharmaceutical IndustryMerck KGaA Buys Silence Therapeutics For $1.1 Billion Enterprise Value, Adding A Phase 3-Ready PV siRNA Program
Merck KGaA said it will acquire Silence Therapeutics for $20 per share, with the companies describing the transaction as about $1.1 billion in enterprise value and about $1.3 billion in equity value. The strategic centerpiece is divesiran, which Silence is using as a springboard into Phase 3 in polycythemia vera after mid-stage data that put it near the front of an increasingly competitive field.
The Catalyst BriefOct 19, 2026
Biotech InnovationGilead Posts Phase 2 Emvistegrast Win In Ulcerative Colitis, Setting Up A 2027 Phase 3 Monotherapy Study
In the ongoing phase 2 Swift trial, 66% of patients on 200 mg of emvistegrast achieved a clinical response at week 12 versus 37% on placebo, while 31% achieved clinical remission versus 8% on placebo. Gilead plans to start a Phase 3 monotherapy study in 2027 and is positioning the oral α4β7 integrin inhibitor as a potential backbone for future combination approaches.
The Catalyst BriefOct 19, 2026
Regulatory & PolicyDisc Medicine Posts Phase 3 Bitopertin Win In EPP, Reopening Its FDA Path After Last Year’s Rejection
Bitopertin reduced whole-blood metal-free protoporphyrin IX and increased time spent in light in APOLLO, according to Disc Medicine. The data matter beyond one trial result because they directly address the FDA’s earlier concern that the biomarker used in the accelerated filing had not shown enough clinical relevance on its own.
The Catalyst BriefOct 19, 2026
Biopharmaceutical IndustryRoche Expands Hansoh ADC Alliance To Up To $15 Billion, Deepening Its China Oncology Sourcing
The new agreement comes a year after Roche licensed ex-China rights to Hansoh’s CDH17-targeted ADC HS-20110. Taken together, the two deals point to a more deliberate strategy of sourcing oncology assets from Chinese developers with established ADC platforms rather than treating such transactions as one-off bets.
The Catalyst BriefOct 19, 2026
Biotech InnovationNouscom Raises $135 Million For NOUS-209, Backing A Registration-Enabling Lynch Syndrome Trial
The Swiss biotech said the series D round will fund development of NOUS-209, an off-the-shelf cancer immunotherapy aimed at preventing tumors in people with Lynch syndrome. Early clinical results cited alongside the raise showed all evaluable carriers remained free from advanced adenomas and colorectal cancer, giving investors a clearer clinical rationale for a prevention-focused program.
The Catalyst BriefOct 19, 2026